• Sourcing Solutions
  • Services & Membership
  • Help & Community

Quick Details

  • CAS No.: 134678-17-4
  • Other Names: (2r-cis)-4-amino-1-[2-(hydroxymethyl)-1
  • MF: C8H11N3O3S
  • EINECS No.: 134678-17-4
  • Place of Origin: Shaanxi, China (Mainland)
  • Type: Antibiotic and Antimicrobial Agents, Vitamins, Amino Acids and Coenzymes
  • Grade Standard: Medicine Grade
  • Usage: Animal Pharmaceuticals
  • Brand Name: Wango
  • Model Number: Lamivudine
  • Purity: 99%
  • Appearance: white powder
  • Molecular Weight: 229.26
  • Melting point: 160~162℃
  • Storage: below 30℃
  • Density: 1.73g/cm3
  • refractive index: -142 ° (C=1, MeOH)

Packaging & Delivery

Packaging Details 1kg/al-foil bag,5KG/al-foil bag,25kg/drum
Delivery Time Shipped in 2 days after payment

                               High quality Lamivudine 99% Cas 134678-17-4 




Product nameLamivudine
CAS NO.134678-17-4
CategoryPharmaceutical Raw Materials,Active Pharmaceutical Ingredients
Molecular Formula C8H11N3O3S
Appearance White Crystalline Powder
Shelf life2 years
StorageLamivudine should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.
Delivery TimeWithin 1-2 working days after receiving the payment




Lamivudine (2′,3′-dideoxy-3′-thiacytidine, commonly called 3TC) is an antiretroviral medication used to prevent and treat HIV/AIDS and used to treat chronic hepatitis B.

It is of the nucleoside analog reverse transcriptase inhibitor (NRTI) class. It is marketed in the United States under the tradenames Epivirand Epivir-HBV.

Medical uses:

Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV/AIDS. It improves theseroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long term use of lamivudine leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.


In HIV, high level resistance is associated with the M184V/I mutation in the reverse transcriptase gene as reported by Raymond Schinazi's group at Emory UniversityGlaxoSmithKline claimed that the M184V mutation reduces "viral fitness", because of the finding that continued lamivudine treatment causes the HIV viral load to rebound but at a much lower level, and that withdrawal of lamivudine results in a higher viral load rebound with rapid loss of the M184V mutation; GSK therefore argued that there may be benefit in continuing lamivudine treatment even in the presence of high level resistance, because the resistant virus is "less fit". The COLATE study has suggested that there is no benefit to continuing lamivudine treatment in patients with lamivudine resistance.[3] A better explanation of the data is that lamivudine continues to have a partial anti-viral effect even in the presence of the M184V mutation.


Mechanism of Action:

Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B virus. It is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

Lamivudine is administered orally, and it is rapidly absorbed with a bio-availability of over 80%. Some research suggests that lamivudine can cross the blood–brain barrier. Lamivudine is often given in combination with zidovudine, with which it is highly synergistic. Lamivudine treatment has been shown to restore zidovudine sensitivity of previously resistant HIV. Lamivudine showed no evidence of carcinogenicity or mutagenicity in in vivo studies in mice and rats at doses from 10 to 58 times those used in humans.

                                                                   Certificat of Analysis




Test Results


White crystalline powder


Light Absorption

Not more than 0.015(440nm,4cm cell, 50mg/ml)





Light absorption(50mg/ml,440nm,4cm)



Limit of Lamivudine enantiomer


Not detected

Salicylic  acid


Not detected

Total impurities



Other individual impurity



Relative retention time at about 0.4 impurity



Relative retention time at about 0.90 impurity



Total residual solvents








Not detected

Methylene dichloride


Not detected



Not detected



Not detected

Ethyl acetate


Not detected



Not detected

Assay(On the anhydrous and solvent-free basis)




About Certificates:

About Transportation:


              High quality Lamivudine 99% Cas 134678-17-4 

Transaction History of the Supplier

Below is the information about the supplier's transactions conducted via Alibaba.com. If you require further details regarding the transaction data, please contact the supplier directly.

Transaction Overview


Transaction Details

This supplier has completedtransactions with buyers from .

Shipping Destination
Transaction Value
Transaction Date
Email to this supplier
China (Mainland)
Transaction Level:
Supplier Assessments:
1 Resolved Substantiated complaints against this supplier in last 90 days.
The supplier supports Trade Assurance – A free service that protects your orders from payment to delivery.
Supplier's Trade Assurance Limit: US $23,000
Learn More

Asia Foresight-care Group Limited 


Xi'An Wango Biochem Co.,Ltd  



Fast delivery service